Shigehiko Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shigehiko Kato has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Tetsu Watanabe
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
3 shared publications - Masafumi Watanabe
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
2 shared publications Satoshi Nishiyama
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan
2 shared publicationsTakanori Arimoto
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan
2 shared publicationsYoichiro Otaki
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan
2 shared publicationsAkira Funayama
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Japan
1 shared publication
Latest Publications
- Open Access
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045155
Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry
Background: Group 2 pulmonary hypertension ( PH ), defined as PH caused due to left heart disease, remains a challenging condition. However, its prognostic impact and implications for emerging therapies are unclear. We aimed to evaluate the real‐world relationship between pulmonary vascular resistance ( PVR ) and prognosis in Group 2 PH and assess the efficacy of emerging therapies. Methods: Two prospective registries supported by Japanese PH societies were analyzed: a current (2018–2024; n=563) and a previous (2012–2016; n=425) registry. The composite end points were hospitalization for heart failure, all‐cause death, ventricular assist device implantation, or cardiac transplantation. Results: Stratified analyses using propensity score–matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH (6‐year event‐free rates, PVR > 3 Wood units versus PVR ≦ 3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%). Consistent patterns were observed in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction subgroups. The use of SGLT2 (sodium‐glucose cotransporter‐2) inhibitors in the current registry was associated with improved outcomes in patients with elevated PVR , showing event‐free rates of 73.8% versus 35.5% in those without treatment. Among multivariate analyses including major treatment options, SGLT2 inhibitor treatment exhibited significant associations with improvement of composite end points. Conclusions: Elevated PVR (>3 Wood units) identified a high‐risk subset of patients with Group 2 PH . The association between the use of SGLT2 inhibitors and better outcomes suggests a potential therapeutic role that warrants further investigation through controlled studies.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045155
Open AccessPrognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry
Background: Group 2 pulmonary hypertension ( PH ), defined as PH caused due to left heart disease, remains a challenging condition. However, its prognostic impact and implications for emerging therapies are unclear. We aimed to evaluate the real‐world relationship between pulmonary vascular resistance ( PVR ) and prognosis in Group 2 PH and assess the efficacy of emerging therapies. Methods: Two prospective registries supported by Japanese PH societies were analyzed: a current (2018–2024; n=563) and a previous (2012–2016; n=425) registry. The composite end points were hospitalization for heart failure, all‐cause death, ventricular assist device implantation, or cardiac transplantation. Results: Stratified analyses using propensity score–matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH (6‐year event‐free rates, PVR > 3 Wood units versus PVR ≦ 3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%). Consistent patterns were observed in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction subgroups. The use of SGLT2 (sodium‐glucose cotransporter‐2) inhibitors in the current registry was associated with improved outcomes in patients with elevated PVR , showing event‐free rates of 73.8% versus 35.5% in those without treatment. Among multivariate analyses including major treatment options, SGLT2 inhibitor treatment exhibited significant associations with improvement of composite end points. Conclusions: Elevated PVR (>3 Wood units) identified a high‐risk subset of patients with Group 2 PH . The association between the use of SGLT2 inhibitors and better outcomes suggests a potential therapeutic role that warrants further investigation through controlled studies.
- 24 October 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 55, 102536
Single-photon emission computed tomography-increase ratio, a potential alternative to positron emission tomography-myocardial flow reserve, is a useful prognostic indicator in patients with known or suspected coronary heart disease at facilities without positron emission tomography
- 24 October 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 55, 102536
Single-photon emission computed tomography-increase ratio, a potential alternative to positron emission tomography-myocardial flow reserve, is a useful prognostic indicator in patients with known or suspected coronary heart disease at facilities without positron emission tomography
- Open Access
- 1 April 2021
- Published by Wiley in Journal of Arrhythmia
- Vol. 37 (2) , 458-459
Visualization of epicardial lead infection using 18F-FDG-PET/CT imaging
(18) F-FDG-PET/CT is promising tool to visualize not only transvenous lead infection but also epicardial lead infection.
- 1 April 2021
- Published by Wiley in Journal of Arrhythmia
- Vol. 37 (2) , 458-459
Open AccessVisualization of epicardial lead infection using 18F-FDG-PET/CT imaging
(18) F-FDG-PET/CT is promising tool to visualize not only transvenous lead infection but also epicardial lead infection.
- 1 July 2016
- Published by Elsevier in Atherosclerosis
- Vol. 250, 133-143
The role of macrophage transcription factor MafB in atherosclerotic plaque stability
- 1 July 2016
- Published by Elsevier in Atherosclerosis
- Vol. 250, 133-143
The role of macrophage transcription factor MafB in atherosclerotic plaque stability